Core Viewpoint - The implementation of drug traceability codes in China aims to enhance drug safety and ensure that all drugs involved in centralized procurement have unique electronic identifiers, thereby preventing counterfeit and substandard drugs from entering the market [1][2]. Group 1: Drug Traceability System - Starting from 2025, all drugs participating in centralized procurement must have traceability codes, which serve as unique electronic identities for each drug package [1]. - The traceability system is designed to provide full-chain transparency in drug management, ensuring that the source, destination, and accountability of drugs can be tracked [2]. - As of February 2025, the National Medical Insurance Information Platform has collected 21.936 billion traceability codes, covering all 31 provinces in China [2]. Group 2: Impact on Drug Safety - The "code-based procurement" approach has effectively reduced drug quality risks and has led to the identification and punishment of illegal activities such as drug reselling and swapping [2]. - The "code-based settlement" mechanism has facilitated precise supervision of medical insurance funds, recovering 27.5 billion yuan in fraudulent claims and identifying 2,008 fraudulent institutions [2]. Group 3: Challenges and Recommendations - Despite advancements, there are still weaknesses in drug safety management, particularly in post-market supervision and the classification of different drug types [3]. - The need for a refined classification and grading management system for various drug types, especially high-risk drugs, is emphasized to prevent treatment failures and adverse reactions [3]. - Recommendations include enhancing the drug traceability system, training specialized personnel, and establishing comprehensive legal frameworks to support the system [5].